Table 1.
Clinical characteristics of three RA patients with IgA glomerulonephritis following anti-TNF-α therapy.
| Case 1 | Case 2 | Case 3 | |
|---|---|---|---|
| Months from first visit to diagnosis of RA | 22 | 24 | 57 |
| Steroids in months | 22 | 5 | 51 |
| Methotrexate in months | 3 | 36 | 23 |
| Prior diabetes | No | Yes | Yes |
| Prior arterial hypertension | No | No | No |
|
| |||
| Months from diagnosis of RA to introduction of biologic treatment | 48 | 34 | 27 |
| DAS28 at biologic treatment introduction | 5.52 | 6.30 | 7.09 |
| DAS28 after biologic treatment introduction | 2.66 | 2.09 | 2.28 |
| TNF-α inhibitor | Adalimumab | Golimumab | Adalimumab |
|
| |||
| Months from introduction of biologic treatment to kidney biopsy | 59 | 36 | 70 |
| Peripheral oedema | No | Yes | Yes |
| 24 h urine proteinuria (g/dU) | 2.25 | 0.47 | 4.55 |
| Erithrocyturia | Yes | No | No |
| Serum creatinine (μmol/L) | 137 | 61 | 81 |
| eGFR (mL/min/1.73 m2) | 54.8 | 112.8 | 68.0 |
| Blood pressure (mmHg) | 175/94 | 160/90 | 170/90 |
| Arterial hypertension | Yes | Yes | Yes |
| Hemoglobin (g/dl) | 13.1 | 11.7 | 10.5 |
| White blood cell count (×109/L) | 7.8 | 7.1 | 13.3 |
| Cholesterol (mmol/L) | 5.7 | 4.6 | 5.6 |
| Triglycerides (mmol/L) | 2.78 | 0.61 | 1.65 |
| Erythrocyte sedimentation rate (mm/h) | 64 | 20 | 100 |
| C-reactive protein (mg/L) | 18.3 | 1.7 | 45.9 |
RA-rheumatoid arthritis; eGFR-estimated glomerular filtration rate.